Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab alone versus pembrolizumab plus chemotherapy in first-line PD-L1-high metastatic NSCLC
NL-OMON20213Phase 3Recruiting
- Start
- Feb 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab, carboplatin, cisplatin, pemetrexed and paclitaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by None. Primary endpoint: Overall response rate. Started Feb 2020; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON20213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20213.